Brokerages Set Sage Therapeutics, Inc. (NASDAQ:SAGE) Target Price at $34.80

Sage Therapeutics, Inc. (NASDAQ:SAGE) has been assigned an average rating of “Hold” from the twenty research firms that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, fifteen have issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $34.80.

A number of equities analysts recently issued reports on SAGE shares. HC Wainwright reissued a “neutral” rating and issued a $25.00 price objective on shares of Sage Therapeutics in a report on Tuesday. StockNews.com upgraded shares of Sage Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 27th. Citigroup started coverage on Sage Therapeutics in a research note on Wednesday, May 29th. They set a “sell” rating and a $8.00 price target for the company. Baird R W upgraded Sage Therapeutics to a “hold” rating in a research report on Wednesday, May 29th. Finally, Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a report on Friday, June 28th.

Sage Therapeutics Trading Down 1.9 %

SAGE opened at $10.82 on Wednesday. The company’s 50-day moving average price is $11.78 and its 200 day moving average price is $18.07. Sage Therapeutics has a fifty-two week low of $9.76 and a fifty-two week high of $49.74.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by ($0.17). Sage Therapeutics had a negative net margin of 552.52% and a negative return on equity of 56.81%. The firm had revenue of $7.90 million for the quarter, compared to analyst estimates of $5.26 million. During the same period last year, the firm posted ($2.46) EPS. The business’s revenue was up 139.4% compared to the same quarter last year. Equities analysts expect that Sage Therapeutics will post -6.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Sage Therapeutics

A number of hedge funds have recently bought and sold shares of SAGE. Virtu Financial LLC bought a new stake in shares of Sage Therapeutics in the first quarter valued at about $187,000. Baker BROS. Advisors LP bought a new position in Sage Therapeutics in the first quarter worth $7,631,000. Bellevue Group AG boosted its stake in Sage Therapeutics by 27.1% during the first quarter. Bellevue Group AG now owns 4,465,544 shares of the biopharmaceutical company’s stock worth $83,684,000 after buying an additional 952,193 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Sage Therapeutics by 69.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 811,934 shares of the biopharmaceutical company’s stock worth $15,217,000 after buying an additional 333,805 shares in the last quarter. Finally, Lazard Asset Management LLC bought a new stake in Sage Therapeutics in the 1st quarter valued at $127,000. 99.22% of the stock is currently owned by institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.